KIT and acute myeloid leukemia: Strictly following the WHO criteria, AML-M0 is characterized by the expression of stem cell (CD117, CD38) and/or myeloid (HLA-DR, CD33, CD13) markers without any other lineage-specific antigen; AUL is defined by the absence of any lineage-specific antigen, i.e., MPO, cCD3, CD79a, and cCD22.